Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant SARS-CoV-2 S protein (B.1.351 or 20C/501Y.V2), trimer, His Tag (MALS verified), 50µg  

Recombinant SARS-CoV-2 S protein (B.1.351 or 20C/501Y.V2), trimer, His Tag (MALS verified), 50µg

Recombinant SARS-CoV-2 S protein (L18F, D80A, D215G, 242-244del, R246I, K417N, E484K, N501Y, D614G, A701V) AA Val 16 - Pro 1213, expressed from human 293 cells (HEK293), trimer, His Tag (MALS verified)

Synonyms: Recombinant, protein, S protein, Spike glycoprotein, S glycoprotein, COVID-19

More details

SPN-C52Hk-50

Availability: within 7 days

540,00 €

Background
It's been reported that Coronavirus  can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Source
Recombinant SARS-CoV-2 S protein trimer, His Tag (SPN-C52Hk) is expressed from human 293 cells (HEK293). It contains AA Val 16 - Pro 1213 (Accession # QHD43416.1). The recombinant protein is expressed from human 293 cells (HEK293) with T4 fibritin trimerization motif and a polyhistidine tag at the C-terminus. Proline substitutions (F817P/ A892P/ A899P/ A942P/ K986P/ V987P) and alanine substitutions (R683A and R685A) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein and abolish the furin cleavage site, respectively. L18F/ D80A/ D215G/ LAL242-244del/ R246I/ K417N/ E484K/ N501Y/ D614G/ A701Vmutations were identified on the spike protein in the SARS-CoV-2 variant (known as B.1.351 or 20C/501Y.V2) which emerged in South Africa.
Predicted N-terminus: Val 16

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 137.6 kDa. The protein migrates as 170-200 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Bioactivity
Please refer to product data sheet.

Storage
Avoid repeated freeze-thaw cycles.
-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution

References

  • "Rapid Increase of SARS-CoV-2 Variant B.1.1.7 Detected in Sewage Samples from England between October 2020 and January 2021" Wilton, Bujaki, Klapsa et al. mSystems (2021)

  • "COVID-19 Spike Protein Induced Phononic Modification in Antibody-Coupled Graphene for Viral Detection Application" Nguyen, Kim, Lindemann et al. ACS Nano (2021)

  • "Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab" Gallo, Capuano, Donnarumma et al. Neurol Sci (2021)